REFERENCES
Therapy with tyrosine kinase inhibitors has replaced a transplant from an HLA-identical sibling as initial therapy of newly diagnosed young persons with chronic-phase chronic myelogenous leukemia (CP CML), a shift is based predominately on comparing survival outcomes from studies of each therapy alone. 1, 2 No prospective study or randomized trial has addressed the question of which therapy approach is better. To address this deficiency, we designed a study of outcomes of imatinib versus HLA-identical sibling transplants in persons with CP CML o55 years o1 year from diagnosis, with little or no prior therapy.
Accepted article preview online 23 May 2013; advance online publication, 14 June 2013 Letters to the Editor Subjects referred to Peking University People's Hospital from April 2001 to March 2010 were evaluated for study-entry. Inclusion criteria included: (1) CML in the first CP using World Health Organization criteria, 3 (2) age p55 years; (3) interval from diagnosis to therapy assignment o1 year; (4) Eastern Cooperative Oncology Group score 0-2 and (5) no prior tyrosine kinase inhibitor therapy. Eligible subjects were assigned to receive imatinib unless they had an HLA-identical sibling in which case they were offered a transplant. Last follow-up was March 2012. The study protocol was registered with Chinese Clinical Trial Registry as ChiCTR-TNC-10000955 (www. chictr.org) and written informed consent was obtained from all subjects.
The starting dose of imatinib was 400 mg/day and was adjusted for response and/or toxicity. Subjects failing imatinib received nilotinib, dasatinib or a transplant. Subjects assigned to an HLA-identical sibling transplant received busulfan and cyclophosphamide, followed by cyclosporine, mycophenolate mofetil and short-term methotrexate. 4 Cytogenetic and molecular responses were monitored by standard techniques. 4, 5 Outcomes' analyses were based mostly on European LeukemiaNet criteria. 6 Lefttruncated and right-censored methods were used to account for differences in interval from diagnosis to starting therapy 7 and results confirmed by analysis without using left truncation (definitions of left-truncated method and adjusted survival probability were given in Supplementary Table 2 ). Left-truncated Cox proportional hazards regression models were used to evaluate the relative risk of subjects receiving imatinib versus a transplant.
Three hundred and forty-eight subjects were assigned to imatinib (N ¼ 176) or a transplant (N ¼ 172). Significant pretherapy differences (Supplementary Table 1) were adjusted for in all analyses. Median follow-up from diagnosis for the 315 survivors was 64 months (range 12-143 months).
One hundred and seventy-four (99%) subjects receiving imatinib achieved a complete hematology response (CHR); 163 (95%), a complete cytogenetic response (CCR); 129 (75%), a major molecular response (MMR) and 75 (44%), a complete molecular response (CMR). Sixteen subjects had an event after a median of 10 months (range 3-24 months). Eight subjects progressed to accelerated phase (AP) or blast phase (BP) at median of 14 months (range 6-24 months). One died of disease progression at 7 months, four received a transplant, two switched to dasatinib or nilotinib and one remained on imatinib. Six-year-adjusted probabilities of event-free survival (EFS), progression-free survival (PFS) and survival with left truncation were 91% (95% confidence interval (CI), 86-95%), 96% (95% CI, 91-98%) and 99% (95% CI, 96-100%) ( Table 1) . At the last follow-up, 149 subjects remained on imatinib (85%), 7 switched to nilotinib or dasatinib because of imatinib resistance, 9 received a transplant because of loss of CHR progression or because they chose to do so and 6 were lost to follow-up (Supplementary Figure 1) .
Forty-two subjects assigned to receive a transplant had an event at a median of 6 months (range 1-83 months) posttransplant. Fifteen subjects who relapsed received imatinib and five, a donor lymphocyte infusion. Four subjects with molecular relapse and four of the seven subjects with cytogenetic relapse achieved a CMR. Among the other three subjects with cytogenetic relapse, one had no response to donor lymphocyte infusion and received a second transplant, one progressed to BP and one died of donor lymphocyte infusion. Five subjects progressed to AP or BP at a median of 36 months (range 8-60 months) post-transplant, 6 died of progression/relapse and 26 died of treatment-related mortality (TRM) at a median of 5 months (range 1-83 months) post-transplant. Six-year-adjusted probabilities of EFS, PFS and survival from diagnosis with left truncation were 74% (95% CI, 67-81%), 78% (95% CI, 71-84%) and 79% (95% CI, 72-85%) ( Table 1) . At the last follow-up, 143 subjects were alive in CMR (Supplementary Figure 1) .
The imatinib cohort had a lower 5-year cumulative incidence function of treatment-related mortality compared with the transplant cohort, none (95% CI, 0-6%) versus 17% (95% CI, 12-23%; P ¼ 0.0002). There was no significant difference in the 5-year cumulative incidence function of progression, 5% (95% CI, 2-9%) for imatinib versus 2% (95% CI, 1-5%; P ¼ 0.22) for transplant. Relative risk of an event (1-EFS), treatment failure (1-PFS) and death (1-survival) for the transplant cohort versus imatinib cohort were 3.6 (95% CI, 2.0 À 6.7; Po0.0001), 5.3 (95% CI, 2.4 À 11.7; Po0.0001) and 42 (95% CI, 6 À 309; P ¼ 0.0003) (Supplementary Table 2 ). Adjusted probabilities of EFS, PFS and survival with the left-truncation approach are shown in the Figure 1 . Similar results were obtained when data were analyzed without left truncation, from the time of therapy assignment or without censoring of subjects switching to another therapy after assignment to imatinib (Supplementary Tables 3-6 and Supplementary Figure 2) . At the last follow-up significantly more transplant subjects had a MMR (100% versus 81%; Po0.001) and a CMR (100% versus 48%; Po0.001) than subjects receiving imatinib, but there was no difference in the proportion of subjects with a CCR (100% versus 98%; P ¼ 0.25). Abbreviations: CI, confidence interval; EFS, event-free survival; PFS, progression-free survival. EFS was defined as interval from diagnosis of chronic myelogenous leukemia (CML) to one of the following:
(1)ocomplete hematological response at 3 months; (2) loss of a complete hematological response, major or complete cytogenetic response; (3) development of additional cytogenetic abnormalities; (4) development of accelerated phase or blast phase or (5) death. PFS was defined as interval from diagnosis to progression or death. Survival was defined as interval from diagnosis to death, switch to alternative treatment or last follow-up. This approach, which adjusts for the inability to ensure comparability of subsequent post-event therapies, is sometimes referred to as alternative treatment-free survival recommended for analysis of studies in CML by the European LeukemiaNet. 6 a Comparing outcomes in the imatinib and transplant cohorts required adjustment for two sources of bias: differences in time to transplant and differences in subject baseline characteristics. A left-truncation method was used to ensure that subjects survived a sufficient length of time to receive a treatment (imatinib or transplant). The starting time point for all time-dependent outcome event analyses was diagnosis of CML. At each time point in this model, the risk set consisted of only subjects whose waiting time to treatment was shorter than the study time and still on-study.
Letters to the Editor
Our survival results with imatinib are better than others, 8, 9 and the survival curve was better than the PFS curve. This is because our definition of survival is similar to 'alternative treatment-free survival', which is a reasonable approach to assess the usefulness of a study-treatment according to current recommendations. 6 As indicated, there was no substantial change in our conclusions whether or not subjects in the imatinib cohort were censored when they were switched to alternative therapies after failing imatinib. Our transplant results are comparable to those of large series. [10] [11] [12] [13] In our study, treatment-related mortality was less, and EFS, PFS and survival was better with imatinib compared with transplants. However, the cumulative incidence function of progression was not significantly better with imatinib and the proportion of subjects with MMRs or CMRs was higher with transplants. As progression was rare in both cohorts, even a study with 348 subjects is insufficiently powered to detect a statistically significant difference. However, if such a difference exists, the magnitude must be quite small. Whether HLA-identical sibling transplants will have better long-term outcomes than imatinib because of better molecular responses needs longer follow-up, but is unlikely to alter our conclusions given the excellent imatinib outcomes. Moreover, there is always the possibility of using an HLA-identical sibling transplant after imatinib failure, a strategy not tested in our study. Other nontransplant studies failed to find that molecular analyses were a better predictor of imatinib therapy outcome than cytogenetics. 14, 15 As outcomes of HLAidentical sibling transplants in young persons with CP CML are as good as or better than outcomes of transplants using alternative donors, it is reasonable to assume that our conclusions apply to other types of transplants in the same clinical setting.
There are several limitations to our study. First, subjects were assigned, not randomized, to receive imatinib or a transplant. Consequently, potentially important prognostic variables, especially interval from diagnosis to starting therapy, differed between the cohorts. We attempted to adjust for these differences using a Cox regression model and left-truncation techniques. However, we obviously could not adjust for unknown prognostic variables that may have differed between the cohorts. Moreover, we do not know the population-based starting denominators of each cohort. It is possible, even likely, that there were important selection biases. As transplant subjects were more often seen at our center than imatinib subjects, there were differences in surveillance of laboratory-based end points. Consequently, the reader may want to give greatest attention to clinical end point, such as progression and death where surveillance biases are absent. A final issue is the markedly longer follow-up in the transplant versus imatinib cohort. Two factors contributed these. First, more subjects enrolled in transplant cohort before 2006 and more in the imatinib cohort after 2006. This likely reflects referral biases: before 2006, transplants were regarded by many as the only cure of CML, [10] [11] [12] [13] whereas after 2006 the possibility of cure (or at least long-term survival) with imatinib gained popularity. 8, 9 Consequently, the reader may want to place greater emphasis on the earlier time points in the Table 1 . Second, we censored subjects who switched to a transplant or another tyrosine kinase inhibitor without progression (N ¼ 16) or who were lost to follow-up (N ¼ 6).
Our study suggests imatinib results in comparable or better outcomes than an HLA-identical sibling transplant as initial therapy of persons with CP CML o55 years o1 year from diagnosis, with little or no prior therapy. Consequently, initial therapy with imatinib may be preferred even in persons with an HLA-identical sibling and, even more likely, in person with an alternative donor. More precise early predictors of persons likely to eventually fail imatinib could change this calculus and/or indicate when a person receiving imatinib should switch to a transplant. However, such a strategy should be confirmed in a prospective study or randomized clinical trial if possible.
